SG11202104217QA - Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof - Google Patents

Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Info

Publication number
SG11202104217QA
SG11202104217QA SG11202104217QA SG11202104217QA SG11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA
Authority
SG
Singapore
Prior art keywords
antibodies
family
sequence similarity
similarity
sequence
Prior art date
Application number
SG11202104217QA
Other languages
English (en)
Inventor
Bongcheol Kim
Wonkyum Kim
Dong Sik Kim
Jae-Keun Lee
Jeongwon Yoon
Junho Chung
Junyeong Jin
Original Assignee
Neuracle Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuracle Science Co Ltd filed Critical Neuracle Science Co Ltd
Publication of SG11202104217QA publication Critical patent/SG11202104217QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202104217QA 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof SG11202104217QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962787711P 2019-01-02 2019-01-02
US201962838190P 2019-04-24 2019-04-24
PCT/IB2019/061461 WO2020141452A1 (en) 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Publications (1)

Publication Number Publication Date
SG11202104217QA true SG11202104217QA (en) 2021-05-28

Family

ID=71407016

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104217QA SG11202104217QA (en) 2019-01-02 2019-12-31 Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof

Country Status (11)

Country Link
US (1) US20220144932A1 (ja)
EP (1) EP3906260A4 (ja)
JP (2) JP2022515960A (ja)
KR (2) KR102656738B1 (ja)
CN (2) CN113195533B (ja)
AU (1) AU2019418141A1 (ja)
BR (1) BR112021008114A2 (ja)
CA (1) CA3117619A1 (ja)
MX (1) MX2021004504A (ja)
SG (1) SG11202104217QA (ja)
WO (1) WO2020141452A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102648762B1 (ko) * 2018-10-16 2024-03-19 주식회사 뉴라클사이언스 항-fam19a5 항체의 용도
CN117881687A (zh) * 2021-07-08 2024-04-12 纽洛可科学有限公司 多肽抑制剂及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2838814T3 (es) * 2012-02-15 2021-07-02 Neuracle Science Co Ltd FAM19A5 para uso en el diagnóstico y tratamiento de daños en el SNC
KR101802411B1 (ko) * 2015-02-17 2017-11-29 울산대학교 산학협력단 Ｆａｍ１９ａ５ 단백질을 포함하는 비만 예방 또는 치료용 조성물 및 이를 이용한 비만 치료제의 스크리닝 방법
KR102431830B1 (ko) * 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
KR20220031738A (ko) * 2017-06-27 2022-03-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
US11746149B2 (en) * 2017-06-27 2023-09-05 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
EP3645039A4 (en) * 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
CN111315774B (zh) * 2017-06-27 2023-12-22 纽洛可科学有限公司 抗fam19a5抗体及其用途

Also Published As

Publication number Publication date
US20220144932A1 (en) 2022-05-12
MX2021004504A (es) 2021-10-01
CN113195533B (zh) 2024-04-26
EP3906260A4 (en) 2022-08-31
CN113195533A (zh) 2021-07-30
KR102656738B1 (ko) 2024-04-16
AU2019418141A1 (en) 2021-05-27
JP2022515960A (ja) 2022-02-24
WO2020141452A1 (en) 2020-07-09
CA3117619A1 (en) 2020-07-09
CN117964756A (zh) 2024-05-03
KR20210068608A (ko) 2021-06-09
KR20240049652A (ko) 2024-04-16
EP3906260A1 (en) 2021-11-10
JP2023052664A (ja) 2023-04-11
BR112021008114A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
EP3535294A4 (en) ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODY AND METHOD OF USING THEREOF
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202110145SA (en) Antibodies against sars-cov-2 and methods of using the same
IL276731A (en) Antibodies against CD73 and methods of using them
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
EP3790898A4 (en) ANTI-FAMILY SEQUENCE 19, ELEMENT A5 ANTIBODIES AND METHODS OF USE THEREOF
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL278821A (en) Anti-SIRPA antibodies and methods of using them
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
EP3852805A4 (en) ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
EP3645044A4 (en) USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
IL270214A (en) Anti-sortilin antibodies and methods of using them
EP3823986A4 (en) USE OF ANTIBODIES DIRECTED AGAINST SEQUENCE FAMILY 19, ELEMENT A5, FOR THE TREATMENT OF NEUROPATHIC PAIN
EP3731867A4 (en) ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE THEREOF
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL262747A (en) Anti-kv1.3 antibodies, methods for their production and use
IL290741A (en) Antibodies against cd-96 and methods of using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
EP3762015A4 (en) METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them